Miranda Withers
Family · Somerset, KYNPI 1427369206
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Grifols USA, LLC accounts for 70.5% of it on its own, with 21 other manufacturers making up the rest. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $42.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$12K
- GSK$962
- Mylan Specialty L.p.$530
- Viatris Specialty LLC$451
- AstraZeneca$445
- Boehringer Ingelheim$374
- plus $2K from 16 others
What the payments were for
- Consulting fees$2001%
- Speaking & faculty fees$6,92041%
- Travel & lodging$3,58621%
- Food & beverage$5,99935%
- Education$3292%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 146 | $12,012 |
| GSK | 72 | $962 |
| Mylan Specialty L.p. | 27 | $530 |
| Viatris Specialty LLC | 23 | $451 |
| AstraZeneca | 14 | $445 |
| Boehringer Ingelheim | 26 | $374 |
| Jazz Pharmaceuticals Inc. | 13 | $345 |
| Harmony Biosciences LLC | 17 | $341 |
| Amgen | 19 | $336 |
| Grifols Shared Services North America, Inc. | 1 | $240 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $200 |
| Sunovion Pharmaceuticals Inc. | 13 | $185 |
| Inspire Medical Systems, Inc. | 3 | $155 |
| Verona Pharma, Inc. | 6 | $133 |
| Electromed, Inc. | 4 | $118 |
| Merck | 4 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| UCB, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $16 |
| Covis Pharma GmbH | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$10,813
- LUMRYZ$200
- Inspire$100
How this compares
$17,033 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 784 | $664,198 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 32 | $418,337 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 203 | $155,544 |
| Spiriva RespimatTiotropium Bromide | 156 | $130,383 |
| Spiriva HandihalerTiotropium Bromide | 131 | $80,116 |
| Breo ElliptaFluticasone/Vilanterol | 129 | $71,450 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $62,114 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $60,491 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 74 | $55,491 |
| Incruse ElliptaUmeclidinium Bromide | 77 | $37,428 |
| Ventolin HfaAlbuterol Sulfate | 511 | $33,861 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,055 | $32,603 |
| NeuproRotigotine | 29 | $27,725 |
| Arnuity ElliptaFluticasone Furoate | 71 | $21,600 |
| Advair HfaFluticasone Propion/Salmeterol | 50 | $18,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $962 | $856,7901,170 claims |
| Grifols USA, LLCProlastin C | $12,012 | $418,33732 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $374 | $246,364329 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $445 | $177,634275 claims |
| UCB, Inc.Neupro | $22 | $27,72529 claims |
| MerckDulera, Asmanex | $67 | $7,86325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Somerset
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
- Carrie Parrish NyekanBowling Green$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.